Cargando…

Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia

Ph+ ALL is a poor-prognosis leukemia subtype driven by the BCR-ABL1 oncogene, either the p190- or the p210-BCR/ABL isoform in a 70:30 ratio. Tyrosine Kinase inhibitors (TKIs) are the drugs of choice in the therapy of Ph+ ALL. In combination with standard chemotherapy, TKIs have markedly improved the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porazzi, Patrizia, De Dominici, Marco, Salvino, Joseph, Calabretta, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467343/ https://www.ncbi.nlm.nih.gov/pubmed/34573335 http://dx.doi.org/10.3390/genes12091355

Ejemplares similares

Targeting the STAT5 pathway in Ph+ acute lymphoblastic leukemia
por: Minieri, Valentina, et al.
Publicado: (2018)

CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia
por: Mariani, Samanta Antonella, et al.
Publicado: (2016)

Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia
por: Bride, Karen L., et al.
Publicado: (2021)

Targeting miR-126 in Ph+ acute lymphoblastic leukemia
por: Qiao, Junjing, et al.
Publicado: (2023)

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia
por: Urtishak, Karen A., et al.
Publicado: (2018)

Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like—Recent Progress in Treatment
por: Kaczmarska, Agnieszka, et al.
Publicado: (2021)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1- induced T cell acute lymphoblastic leukemia
por: Jena, Nilamani, et al.
Publicado: (2015)

BCL6 enables Ph(+) acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition
por: Duy, Cihangir, et al.
Publicado: (2011)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

Obesity in patients with acute lymphoblastic leukemia in childhood
por: Iughetti, Lorenzo, et al.
Publicado: (2012)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Targeting chemokines for acute lymphoblastic leukemia therapy
por: Hong, Zixi, et al.
Publicado: (2021)

Targeting Telomere Biology in Acute Lymphoblastic Leukemia
por: Karow, Axel, et al.
Publicado: (2021)

PHF6 mutations in T-cell acute lymphoblastic leukemia
por: Van Vlierberghe, Pieter, et al.
Publicado: (2010)

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
por: Sorf, Ales, et al.
Publicado: (2020)

Acute lymphoblastic leukemia
por: Schrappe, Martin
Publicado: (2018)

miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6)
por: Zhou, Hong, et al.
Publicado: (2021)

A Novel t(5;7)(q31;q21)/CDK6::IL3 in Immature T-cell Acute Lymphoblastic Leukemia With IL3 Expression and Eosinophilia
por: Pierini, Valentina, et al.
Publicado: (2022)

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
por: Liu, Wei, et al.
Publicado: (2021)

Targeting IRAK1 in T-Cell acute lymphoblastic leukemia
por: Dussiau, Charles, et al.
Publicado: (2015)

Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia
por: Dobrovinskaya, Oxana, et al.
Publicado: (2016)

Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells
por: Spagnuolo, Manuela, et al.
Publicado: (2019)

The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations
por: Fang, Qiuyun, et al.
Publicado: (2022)

Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease
por: Liam, Christopher Chin Keong, et al.
Publicado: (2022)

BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy
por: Slone, William L., et al.
Publicado: (2016)

Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia
por: Alsous, Mervat, et al.
Publicado: (2017)

P359: DOUBLE-HIT LEUKEMIA: A VERY HIGH-RISK SUBTYPE PH-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Huang, Zicong, et al.
Publicado: (2023)

PB1975: ABL1 GENE DNA SEQUENCING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Kuzmina, Elena, et al.
Publicado: (2023)

Acute lymphoblastic leukemia in adults
por: Ribera, Josep-Maria
Publicado: (2011)

Pediatric acute lymphoblastic leukemia
por: Inaba, Hiroto, et al.
Publicado: (2020)

Targeting survivin and p53 in pediatric acute lymphoblastic leukemia
por: Tyner, J W, et al.
Publicado: (2012)

Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia
por: Zhang, Cheng, et al.
Publicado: (2015)

Targeted genome editing in acute lymphoblastic leukemia: a review
por: Montaño, Adrián, et al.
Publicado: (2018)

Targeting PI3K Signaling in Acute Lymphoblastic Leukemia
por: Sanchez, Vanessa Edna, et al.
Publicado: (2019)

Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia
por: Xu, Huan, et al.
Publicado: (2021)

Translocation t(2;14)(p13;q32) in a case of Ph+ acute lymphoblastic leukemia
por: Kerketta, Lily, et al.
Publicado: (2007)

Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients
por: Zhu, Yu, et al.
Publicado: (2014)

Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia
por: Yu, Guopan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d87c7f4ej563o14erkpk5gkb4s